N
AKBA icon

Nuveen’s Akebia Therapeutics AKBA Stock Holding History

Nuveen’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$829K Buy
596,599
+3,608
+0.6% +$4.96K ﹤0.01% 2662
2025
Q4 		$955K Sell
592,991
-1,708,386
-74% -$3.58M ﹤0.01% 2638
2025
Q3 		$6.28M Sell
2,301,377
-407,299
-15% -$1.35M ﹤0.01% 1800
2025
Q2 		$9.86M Buy
2,708,676
+2,358,263
+673% +$6.48M ﹤0.01% 1514
2025
Q1 		$20.5M Sell
350,413
-30,122
-8% -$61.5K 0.01% 1122
2024
Q4 		$723K Hold
380,535
– – ﹤0.01% 2840
2024
Q3 		$502K Hold
380,535
– – ﹤0.01% 3018
2024
Q2 		$388K Buy
+380,535
New +$470K ﹤0.01% 3076
2022
Q1 		– Sell
-580,106
Closed -$1.33M – 3390
2021
Q4 		$1.33M Buy
580,106
+7,107
+1% +$19.4K ﹤0.01% 2744
2021
Q3 		$1.66M Sell
572,999
-7,011
-1% -$20K ﹤0.01% 2759
2021
Q2 		$2.2M Buy
580,010
+63,267
+12% +$213K ﹤0.01% 2665
2021
Q1 		$1.75M Sell
516,743
-300
-0.1% -$1.08K ﹤0.01% 2680
2020
Q4 		$5.17M Sell
517,043
-1,154,823
-69% -$3.37M ﹤0.01% 2054
2020
Q3 		$16.7M Buy
1,671,866
+98,926
+6% +$868K 0.01% 1180
2020
Q2 		$21.4M Buy
1,572,940
+87,084
+6% +$901K 0.01% 1000
2020
Q1 		$11.3M Sell
1,485,856
-241,427
-14% -$1.88M 0.01% 1220
2019
Q4 		$10.9M Buy
1,727,283
+13,777
+0.8% +$65.5K ﹤0.01% 1543
2019
Q3 		$6.72M Buy
1,713,506
+84,478
+5% +$362K ﹤0.01% 1794
2019
Q2 		$7.88M Buy
+1,629,028
New +$9.27M ﹤0.01% 1748

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen's AKBA Position: Q1 2026 in Review

Nuveen increased its Akebia Therapeutics (AKBA) stake by 0.61% in Q1 2026, buying an estimated $4.96K and bringing the position to 596,599 shares worth $829K. The position accounts for ﹤0.01% of the portfolio, ranked #2662.

Nuveen first reported a position in AKBA in Q2 2019 and has held it in 19 quarters since. The position peaked at $21.4M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Nuveen held 596,599 shares of Akebia Therapeutics worth $829K as of Q1 2026.
  • Nuveen bought 3,608 Akebia Therapeutics shares in Q1 2026, an estimated $4.96K.
  • Akebia Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2662 holding.
  • Nuveen first reported a position in Akebia Therapeutics in Q2 2019 and has held it in 19 quarters since.
  • Nuveen's Akebia Therapeutics position peaked at $21.4M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.